The GLP-1 revolution, which started with relatively modest single-agonist drugs, has progressed to dual-agonists, then triple-agonists, and the pipeline continues to expand
How GLP-1 dry mouth compares to other medication-induced dry mouth GLP-1 medications are far from the only drugs that cause dry mouth
Endocrinology 144 (5), 20552067
Retatrutide shows 24.2% average weight loss at 48 weeks in Phase 2 trials, compared to 14.9% weight loss for semaglutide at 68 weeks
Making your decision: the practical framework After reviewing all the dosage data, side effects, timelines, and mechanisms, the decision between retatrutide and tirzepatide comes down to a handful of practical questions
By connecting prescription therapy with evidence-based behavior change and daily support, Noom helps people not only lose weight but maintain their results long after treatment ends